Health and Human Services Department, Food and Drug Administration
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Oscar Bobo for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Bobo engaged in a pattern of importing or offering for import misbranded drugs (i.e., in an amount, frequency, or dosage that is inconsistent with his personal or household use) that are not designated in an authorized electronic data interchange system as products regulated by FDA. Mr. Bobo was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of March 25, 2026 (30 days after receipt of the notice), Mr. Bobo had not responded. Mr. Bobo's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.
Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Health and Human Services Food and Drug Administration [Docket No. FDA-2025-N-0421] AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Oscar Bobo for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Bobo engaged in a pattern of importing or offering for import misbranded drugs ( i.e., in an amount, frequency, or dosage that is inconsistent with his personal or household use) that are not designated in an authorized electronic data interchange system as products regulated by FDA. Mr. Bobo was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of March 25, 2026 (30 days after receipt of the notice), Mr. Bobo had not responded. Mr. Bobo's failure to ( printed page 27963) respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter. DATES: This order is applicable May 15, 2026. ADDRESSES: Any application by Mr. Bobo for termination of debarment under section 306(d)(1) of the FD&C Act ( 21 U.S.C. 335a(d)(1) ) may be submitted at any time as follows: Electronic Submissions Federal eRulemaking Portal: https://www.regulations.gov . Follow the instructions for submitting comments. An application submitted el…
Citation: 91 FR 27962
